[go: up one dir, main page]

GB202211117D0 - Compositions and methods for non-immunogenecity - Google Patents

Compositions and methods for non-immunogenecity

Info

Publication number
GB202211117D0
GB202211117D0 GBGB2211117.3A GB202211117A GB202211117D0 GB 202211117 D0 GB202211117 D0 GB 202211117D0 GB 202211117 A GB202211117 A GB 202211117A GB 202211117 D0 GB202211117 D0 GB 202211117D0
Authority
GB
United Kingdom
Prior art keywords
immunogenecity
compositions
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2211117.3A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Replay Holdings Inc
Original Assignee
Replay Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Replay Holdings Inc filed Critical Replay Holdings Inc
Priority to GBGB2211117.3A priority Critical patent/GB202211117D0/en
Publication of GB202211117D0 publication Critical patent/GB202211117D0/en
Priority to PCT/US2023/071272 priority patent/WO2024026495A1/en
Priority to JP2025504697A priority patent/JP2025527206A/en
Priority to EP23847615.4A priority patent/EP4562030A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB2211117.3A 2022-07-29 2022-07-29 Compositions and methods for non-immunogenecity Ceased GB202211117D0 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
GBGB2211117.3A GB202211117D0 (en) 2022-07-29 2022-07-29 Compositions and methods for non-immunogenecity
PCT/US2023/071272 WO2024026495A1 (en) 2022-07-29 2023-07-28 Compositions and methods for non-immunogenicity
JP2025504697A JP2025527206A (en) 2022-07-29 2023-07-28 Compositions and methods for non-immunogenicity
EP23847615.4A EP4562030A1 (en) 2022-07-29 2023-07-28 Compositions and methods for non-immunogenicity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2211117.3A GB202211117D0 (en) 2022-07-29 2022-07-29 Compositions and methods for non-immunogenecity

Publications (1)

Publication Number Publication Date
GB202211117D0 true GB202211117D0 (en) 2022-09-14

Family

ID=84540618

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2211117.3A Ceased GB202211117D0 (en) 2022-07-29 2022-07-29 Compositions and methods for non-immunogenecity

Country Status (4)

Country Link
EP (1) EP4562030A1 (en)
JP (1) JP2025527206A (en)
GB (1) GB202211117D0 (en)
WO (1) WO2024026495A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001266787A1 (en) * 2000-06-07 2002-01-08 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2003054152A2 (en) * 2001-12-10 2003-07-03 Nuvelo, Inc. Novel nucleic acids and polypeptides
CA2988854A1 (en) * 2015-05-08 2016-11-17 President And Fellows Of Harvard College Universal donor stem cells and related methods
CA3049766A1 (en) * 2017-01-13 2018-07-19 The Regents Of The University Of California Immunoengineered pluripotent cells
MX2023001831A (en) * 2020-08-13 2023-06-29 Sana Biotechnology Inc METHODS OF TREATMENT OF SENSITIZED PATIENTS WITH HYPOIMMUNOGENIC CELLS AND ASSOCIATED METHODS AND COMPOSITIONS.

Also Published As

Publication number Publication date
WO2024026495A1 (en) 2024-02-01
EP4562030A1 (en) 2025-06-04
JP2025527206A (en) 2025-08-20

Similar Documents

Publication Publication Date Title
GB202111040D0 (en) Compositions and methods
IL318706A (en) Compositions and methods for inducing ferroptosis
GB202108585D0 (en) Methods and compositions
GB202004677D0 (en) Methods and compositions
GB202316199D0 (en) Compositions and methods and uses thereto
GB202217944D0 (en) Compositions and method
IL304824A (en) Fospropofol methods and compositions
GB202116554D0 (en) Methods and compositions
GB202110091D0 (en) Methods and compositions
GB202211117D0 (en) Compositions and methods for non-immunogenecity
IL321428A (en) Compositions and methods
GB202316106D0 (en) Methods and compositions
GB202316109D0 (en) Methods and compositions
GB202311858D0 (en) Methods and compositions
GB202308901D0 (en) Methods and compositions
GB202307563D0 (en) Methods and compositions
GB202305427D0 (en) Methods and compositions
GB202304240D0 (en) Compositions and methods
IL315882A (en) Anti-ilt4 compositions and methods
GB202219851D0 (en) Compositions and methods
GB202306393D0 (en) Trna-based methods and related compositions
GB202209588D0 (en) Methods and compositions
GB202209115D0 (en) Compositions and methods
GB202206268D0 (en) Compositions and methods
GB202205579D0 (en) Methods and compositions

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)